Variables | OR | 95% CI | |
---|---|---|---|
Age | 0.5988 | 0.9937 | 0.9702–1.0176 |
D/R HLA compatibility | 0.0142 | 0.4276 | 0.2144–0.8385 |
Recipient CMV IgG status | <0.0001 | 16.2592 | 4.8663–76.9165 |
Donor CMV IgG status | 0.1884 | 0.5834 | 0.2570–1.2944 |
Donor sex | 0.1606 | 1.6562 | 0.8250–3.3949 |
0.0238 | 0.4701 | 0.2417–0.8988 |
No CMV (pg/mL) | CMV [pg/mL] | No cGvHD (pg/mL) | cGvHD (pg/mL) | |
---|---|---|---|---|
Mean | 67.13 | 96.85 | 62.47 | 116.2 |
SD | 54.23 | 72.04 | 49.88 | 77.03 |
Std. Error | 8.47 | 12.18 | 6.73 | 15.72 |
25–75% percentile | 25.38–94.86 | 39.42–129.8 | 26.53–88.25 | 71.60–145.2 |
95% CI | 50.01–84.25 | 72.10–121.6 | 48.98–75.95 | 83.69–148.7 |
N = 232 | |
---|---|
Age (years, median, range) | 50, 18–73 |
Sex (M/F) | 135 (58.19%)/97 (41.81%) |
Type of donor | |
MSD | 107 (46.12%) |
MUD | 54 (23.28%) |
Haploidentical | 53 (22.84%) |
MMSD | 17 (7.33%) |
Diagnosis | |
AML | 92 (39.66%) |
ALL | 29 (14.50%) |
MDS | 25 (12.50%) |
NHL | 18 (9%) |
MPN | 17 (8.50%) |
HL | 10 (5%) |
PCM | 8 (4%) |
Other | 33 (16.50%) |
Conditioning | |
RIC/MAC/NMA | 104 (44.83%)/125 (53.88%)/3 (1.29%) |
Post-transplant complications | |
aGvHD (I–IV) | 91 (39.22%) |
aGvHD (II–IV) | 48 (20.69%) |
cGvHD | 46 (19.83%) |
cGvHD de novo/progression of aGvHD to cGvHD/after aGvHD remission | 17 (36.96%)/8 (17.39%)/20 (43.48%) |
CMV | 90 (38.79%) |
Relapse | 31 (13.36%) |
Death | 30 (12.93%) |
No complications |
83 (35.78%) |
Variant | rs1065057 | rs3828903 |
---|---|---|
91.47 pg/mL | 90.45 pg/mL | |
74.95 pg/mL | 90.48 pg/mL | |
39.78 pg/mL | 63.49 pg/mL |